Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 8/20 | 0.53 |
| ▸ | CA2 | P00918 | 8/20 | 0.53 |
| ▸ | CA12 | O43570 | 7/20 | 0.53 |
| ▸ | CA9 | Q16790 | 7/20 | 0.53 |
| ▸ | STK17B | O94768 | 1/20 | 0.50 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8959096 | 0.94 | TDP1 (0.68) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL28636908 | 0.92 | TDP1 (0.71) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL1486465 | 0.92 | TDP1 (0.71) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL28630680 | 0.92 | TDP1 (0.71) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL1531287 | 0.88 | TDP1 (0.58) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL569251 | 0.87 | TDP1 (0.74) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL3020258 | 0.87 | TDP1 (0.81) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL25756212 | 0.86 | TDP1 (0.54) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL25770346 | 0.86 | TDP1 (0.58) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL3025184 | 0.85 | TDP1 (0.85) | TDP1MEN1GAAKMT2AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 217 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119775227-A | Roxatidine intermediate Synthesis process of intermediate 3 | 浙江华纳药业有限公司 | 2025-04-08 | — | — | CN | claimed |
| CN-119080663-A | Efficient low-cost synthesis method of azetidine hydrochloride | 南宁师范大学 | 2024-12-06 | — | — | CN | claimed |
| US-20260115187-A1 | TRICYCLIC SKELETON COMPOUND AND USE THEREOF IN PREPARATION OF ANTITUMOR DRUG | ZHONGSHAN HOSPITAL, FUDAN UNIVERSITY (CN) | 2026-04-30 | — | — | US | disclosed |
| US-20260078099-A1 | COMPOUND, PREPARATION METHOD THEREOF, AND LIPID NANOPARTICLE AND PHARMACEUTICAL COMPOSITION | SUZHOU HEALIRNA BIOTECHNOLOGY CO., LTD. (CN) | 2026-03-19 | — | — | US | disclosed |
| EP-4705278-A1 | ANTIMICROBIAL CONJUGATED OLIGOELECTROLYTES AS BROAD-SPECTRUM ANTIBIOTICS | The Regents of University of California (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4650349-A1 | COMPOUND, PREPARATION METHOD, AND LIPID NANOPARTICLES AND PHARMACEUTICAL COMPOSITION THEREOF | Suzhou Healirna Biotechnology Co., Ltd. (CN) | 2025-11-19 | — | — | EP | disclosed |
| CN-119775227-A | Roxatidine intermediate Synthesis process of intermediate 3 | 浙江华纳药业有限公司 | 2025-04-08 | — | — | CN | disclosed |
| US-20250066335-A1 | POLYSUBSTITUTED 4-HYDROXYPYRIDINE AND 4-HYDROXYQUINOLINE DERIVATIVES AS GPR84 ANTAGONISTS | UNIVERSITY OF COPENHAGEN (DK) | 2025-02-27 | — | — | US | disclosed |
| EP-4486453-A1 | BENZAMIDE COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | F. Hoffmann-La Roche AG (CH) | 2025-01-08 | — | — | EP | disclosed |
| CN-119080663-A | Efficient low-cost synthesis method of azetidine hydrochloride | 南宁师范大学 | 2024-12-06 | — | — | CN | disclosed |
| CN-119080663-A | Efficient low-cost synthesis method of azetidine hydrochloride | 南宁师范大学 | 2024-12-06 | — | — | CN | disclosed |
| WO-1999018073-A1 | AZETIDINONE DERIVATIVES FOR THE TREATMENT OF HCMV INFECTIONS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 1999-04-15 | — | — | WO | disclosed |
| US-5773465-A | Tartronic acids, their acetalic ethers and o-esters | DOMPE FARMACEUTICI S.P.A. (IT) | 1998-06-30 | — | — | US | disclosed |
| US-5656656-A | Tartronic acids, their acetalic ethers and O-esters | DOMPE FARMACEUTICI S.P.A. (IT) | 1997-08-12 | — | — | US | disclosed |
| EP-0667850-B1 | TARTRONIC ACIDS, THEIR ACETALIC ETHERS AND O-ESTERS | DOMPE FARMACEUTICI SPA (IT) | 1997-05-28 | — | — | EP | disclosed |
| EP-0667850-A1 | TARTRONIC ACIDS, THEIR ACETALIC ETHERS AND O-ESTERS. | DOMPE FARMACEUTICI SPA (IT) | 1995-08-23 | — | — | EP | disclosed |
| WO-1994010127-A1 | TARTRONIC ACIDS, THEIR ACETALIC ETHERS AND O-ESTERS | DOMPE' FARMACEUTICI S.P.A. (IT) | 1994-05-11 | — | — | WO | disclosed |
| EP-0254080-B1 | MALONIC ACID DERIVATIVES AND METHODS FOR THEIR SYNTHESIS | ENIRICERCHE S.p.A. (IT) | 1993-03-17 | — | — | EP | disclosed |
| US-4914226-A | Malonic acid derivatives and methods for their synthesis | ENIRICERCHE S.P.A. (IT) | 1990-04-03 | — | — | US | disclosed |
| EP-0254080-A2 | Malonic acid derivatives and methods for their synthesis | ENIRICERCHE S.p.A. (IT) | 1988-01-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078099-A1 | COMPOUND, PREPARATION METHOD THEREOF, AND LIPID NANOPARTICLE AND PHARMACEUTICAL COMPOSITION | SGMS1, LDLR, NR5A1 | TDP1 1929/4885MEN1 317/4885GAA 3827/4885 |
| US-20260115187-A1 | TRICYCLIC SKELETON COMPOUND AND USE THEREOF IN PREPARATION OF ANTITUMOR DRUG | HCCS, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MCL1 | TDP1 4399/4885MEN1 903/4885GAA 4268/4885 |
| US-20250066335-A1 | POLYSUBSTITUTED 4-HYDROXYPYRIDINE AND 4-HYDROXYQUINOLINE DERIVATIVES AS GPR84 ANTAGONISTS | GPR84, GPR88, GPR65 | TDP1 3144/4885MEN1 4705/4885GAA 1453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.